Skip to main content

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Questcor Pharmaceuticals



) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day up 0.4%. By the end of trading, Questcor Pharmaceuticals rose $3.41 (5.0%) to $71.84 on average volume. Throughout the day, 1,900,823 shares of Questcor Pharmaceuticals exchanged hands as compared to its average daily volume of 1,973,000 shares. The stock ranged in a price between $68.47-$72.43 after having opened the day at $68.54 as compared to the previous trading day's close of $68.43. Other companies within the Health Care sector that increased today were:

Sunshine Heart



), up 21.0%,

GW Pharmaceuticals PLC ADR



), up 17.9%,

Prana Biotechnology



Scroll to Continue

TheStreet Recommends

), up 17.5% and

Escalon Medical Corporation



), up 17.5%.

Questcor Pharmaceuticals, Inc., a biopharmaceutical company, provides drugs for the treatment of multiple sclerosis, nephrotic syndrome, and infantile spasms indications. It primarily offers H.P. Questcor Pharmaceuticals has a market cap of $4.1 billion and is part of the drugs industry. Shares are up 153.9% year to date as of the close of trading on Thursday. Currently there are 6 analysts that rate Questcor Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates

Questcor Pharmaceuticals

as a


. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.

On the negative front,

Mast Therapeutics



), down 42.7%,




), down 28.8%,

Ambit Biosciences



), down 10.4% and

Biostar Pharmaceuticals



), down 9.1% , were all laggards within the health care sector with

Warner Chilcott



) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider

Health Care Select Sector SPDR



) while those bearish on the health care sector could consider

ProShares Ultra Short Health Care




3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.